Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDM for Optimization of Heart Failure Pharmacotherapy
NCT06035978Phase 4Not yet recruiting
- Sponsor
- University Hospital Ostrava
- Start
- Mar 2024
- Primary completion
- Apr 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of nebivolol, sacubitril + valsartan, carvedilol, bisoprolol, metoprolol in heart failure with reduced ejection fraction (HFrEF), sponsored by University Hospital Ostrava. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
nebivololsacubitril + valsartancarvedilolbisoprololmetoprolol
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT06035978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06035978.